A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers

This study is researching an experimental CAR T cell therapy called 27T51, referred to as study drug. The study drug is a MUC16 targeting immune cell therapy focused on adult female participants with recurrent or difficult to treat epithelial ovarian, primary peritoneal or fallopian tube cancer. This study has two (2) major parts: Phase 1a Dose Escalation and Phase 1b Dose Expansion. The aim of the dose escalation part will be to test the safety of 27T51 in a small number of participants to find the highest dose given to humans without unacceptable side effects. The aim of the dose expansion

Trial Details

NCT ID
NCT06469281
Phase
PHASE1
Sponsor
Regeneron Pharmaceuticals
Status
RECRUITING
Cancer Type
Ovarian Cancer
Interventions
  • 27T51
  • Cemiplimab
  • Bevacizumab
Locations (sample)
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Hackensack, New Jersey, United States|40.88593,-74.04347
  • Buffalo, New York, United States|42.88645,-78.87837
  • Pittsburgh, Pennsylvania, United States|40.44062,-79.99589
  • Salt Lake City, Utah, United States|40.76078,-111.89105

Key Eligibility Criteria

  • Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1
  • Histological diagnosis of epithelial ovarian, primary peritoneal, or fallopian tube cancer according to World of Health Organization (WHO) 2020 cla…
  • Recurrent or refractory epithelial ovarian, primary peritoneal, or fallopian tube cancer, as described in the protocol
  • Serum cancer antigen (CA) 125 ≥ 2 × upper limit of normal (ULN) as assessed at the local lab by a 510(k) cleared test at screening

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Ovarian Cancer Trials on Trialify →